Product Description
Mechanisms of Action: GlyT1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Taiwan
Approved Indications: None
Company: China Medical University Hospital
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Depressive Disorder, Major
Phase 2: Obsessive-Compulsive Disorder|Depressive Disorder, Major|Schizophrenia|Psychotic Disorders
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02462447 |
HUM00091201 | N/A |
Completed |
Prostate Cancer |
2017-02-08 |
2019-03-20 |
Treatments |
|
NCT01785628 |
DMR98-IRB-296 | N/A |
Completed |
Dementia|Parkinson's Disease |
2012-06-01 |
2019-03-19 |
Treatments |
|
NCT01503359 |
PULSAR | P2 |
Completed |
Schizophrenia |
2015-02-01 |
2021-05-19 |
Primary Endpoints |
|
NCT01047592 |
DMR98-IR-014 | P2 |
Completed |
Schizophrenia |
2013-12-01 |
2019-03-19 |
Treatments |
|
NCT00977353 |
DOH95-TD-B-111-TM002 | P2 |
Completed |
Depressive Disorder, Major |
2011-07-01 |
2019-03-19 |
Treatments |
|
NCT01031927 |
DMR96-IRB-75 | P2 |
Completed |
Obsessive-Compulsive Disorder |
2009-02-01 |
2019-03-19 |
Treatments |
|
NCT00491569 |
Sarcosine vs. D-Serine | P2 |
Completed |
Psychotic Disorders|Schizophrenia |
None |
2019-03-21 |
Treatments |
|
NCT00328276 |
DMR93-IRB-119 | P2 |
Completed |
Schizophrenia|Psychotic Disorders |
None |
2019-03-21 |
Treatments |
|
NCT00276263 |
Heresco 3 CTIL | P2 |
Withdrawn |
Schizophrenia|Psychotic Disorders |
None |
2019-03-21 |
Treatments |
|
NCT04975100 |
IEC/AIIMSBBSR/PGThesis/21/07 | P4 |
Completed |
Depressive Disorder, Major |
2023-04-30 |
2023-07-26 |
Primary Endpoints |